MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Sarcomatoid

Less common than epithelioid mesothelioma, only 7% to 20% of mesothelioma are sarcomatoid. Often called the “wild” type because of it’s unpredictable nature.

National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

The Annals of Thoracic Surgery 2017 December [Epub ahead of print] [Link] Saddoughi SA, Abdelsattar ZM, Blackmon SH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) remains an aggressive malignancy that is difficult to cure. However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. This study examined the national trends in […]

Comments Off on National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats

Cancer Science 2017 November 29 [Epub ahead of print] [Link] Ohara Y, Chew SH, Shibata T, Okazaki Y, Yamashita K, Toyokuni S Abstract Malignant mesothelioma (MM) is a rare but socially important neoplasm due to its association with asbestos exposure. While MM is difficult to diagnose at an early stage, there are no particularly effective […]

Comments Off on Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats

Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Oncoimmunology 2017 July [Link] Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC Abstract Background: Programmed Cell Death 1-Ligand 1 (PD-L1) and Programmed Death Protein 1 (PD-1) blocking antibodies are promising immunotherapies for malignancies. We have previously shown PD-L1 expression in 40% of malignant mesothelioma (MM); however, the temporal and spatial heterogeneity of its […]

Comments Off on Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Chinese Journal of Pathology 2017 October [Link] Guo ZY, Sun WY, Michele Y, Zhang JL, Hu D, Su HN, Yang WM, Mao W Abstract Objective: To investigate the expression of BRCA-associated protein 1 (BAP1) in malignant mesothelioma, non-small cell lung cancer and carcinosarcoma, and its application in the differential diagnosis. Methods: Twenty-two cases of malignant […]

Comments Off on Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation

The American Journal of Dermatopathology 2017 October [Epub ahead of print] [Link] Klebanov N, Reddy BY, Husain S, Silvers DN, Grossman ME, Tsao H Abstract Malignant pleural mesothelioma is a rare neoplasm of mesodermal origin. Cutaneous involvement of malignant pleural mesothelioma is a very rare entity, with only 11 cases reported in the literature. Here, […]

Comments Off on Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation

Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Oncotarget 2017 August [Link] Wang LM, Shi ZW, Wang JL, Lv Z, Du FB, Yang QB, Wang Y Abstract BACKGROUND: Conventional measurements are not always helpful in the diagnosis of malignant mesothelioma (MM). Increasing studies indicate that loss of BRCA1-associated protein 1 (BAP1) detected by immunohistochemistry (IHC) is a useful diagnostic marker for MM. In […]

Comments Off on Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Comments Off on Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma

Oncotarget 2017 February [Link] Pouliquen DL, Nawrocki-Raby B, Nader J, Blandin S, Robard M, Birembaut P, Grégoire M Abstract A rat model of sarcomatoid mesothelioma, mimicking some of the worst clinical conditions encountered, was established to evaluate the therapeutic potential of intracavitary curcumin administration. The M5-T1 cell line, selected from a collection established from F344 […]

Comments Off on Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Human Pathology 2017 August 12 [Epub ahead of print] [Link] Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M Abstract Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. […]

Comments Off on Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Human Pathology 2017 August 4 [Epub ahead of print] [Link] Marchevsky AM, et. al. Abstract Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype […]

Comments Off on The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.